These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 16732702)

  • 1. Neurocardiogenic syncope: latest pharmacological therapies.
    Chen LY; Shen WK
    Expert Opin Pharmacother; 2006 Jun; 7(9):1151-62. PubMed ID: 16732702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategy for the management of vasovagal syncope.
    Bloomfield DM
    Drugs Aging; 2002; 19(3):179-202. PubMed ID: 12027777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical therapy of neurocardiogenic syncope.
    Cadman CS
    Cardiol Clin; 2001 May; 19(2):203-13, v. PubMed ID: 11407106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of midodrine hydrochloride in patients with refractory vasovagal syncope.
    Samniah N; Sakaguchi S; Lurie KG; Iskos D; Benditt DG
    Am J Cardiol; 2001 Jul; 88(1):A7, 80-3. PubMed ID: 11423066
    [No Abstract]   [Full Text] [Related]  

  • 5. A case of neurally mediated syncope induced by laughter successfully treated with combination of propranolol and midodrine.
    Amaki M; Kamide K; Takiuchi S; Niizuma S; Horio T; Kawano Y
    Int Heart J; 2007 Jan; 48(1):123-7. PubMed ID: 17379987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Midodrine hydrochloride is safe and effective in older people with neurocardiogenic syncope.
    Paling D; Vilches-Moraga A; Akram Q; Atkinson O; Staniland JR; Paredes-Galán E
    J Am Geriatr Soc; 2010 Oct; 58(10):2026-7. PubMed ID: 20929474
    [No Abstract]   [Full Text] [Related]  

  • 7. [Comparative efficacy and tolerance of atenolol and midodrine in patients with vasovagal syncopes].
    Kuchinskaia EA; Pevzner AV; Vershuta EV; Al'bitskaia KV; Kheĭmets GI; Rogoza AN; Golitsyn SP
    Ter Arkh; 2006; 78(4):64-8. PubMed ID: 16821426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathophysiology and management of neurocardiogenic syncope.
    Nair N; Padder FA; Kantharia BK
    Am J Manag Care; 2003 Apr; 9(4):327-34; quiz 335-6. PubMed ID: 12703677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Midodrine: a role in the management of neurocardiogenic syncope.
    Ward CR; Gray JC; Gilroy JJ; Kenny RA
    Heart; 1998 Jan; 79(1):45-9. PubMed ID: 9505918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective evaluation of a two-step therapeutic strategy in neurocardiogenic syncope: midodrine as second line treatment in patients refractory to beta-blockers.
    Klingenheben T; Credner S; Hohnloser SH
    Pacing Clin Electrophysiol; 1999 Feb; 22(2):276-81. PubMed ID: 10087541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent syncope in a 31-year-old army staff sergeant.
    Wiley TM; Luu VD
    Mil Med; 2002 Mar; 167(3):263-5. PubMed ID: 11901579
    [No Abstract]   [Full Text] [Related]  

  • 12. Usefulness of midodrine in patients with severely symptomatic neurocardiogenic syncope: a randomized control study.
    Perez-Lugones A; Schweikert R; Pavia S; Sra J; Akhtar M; Jaeger F; Tomassoni GF; Saliba W; Leonelli FM; Bash D; Beheiry S; Shewchik J; Tchou PJ; Natale A
    J Cardiovasc Electrophysiol; 2001 Aug; 12(8):935-8. PubMed ID: 11513446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurocardiogenic syncope in children : current concepts in diagnosis and management.
    Massin M
    Paediatr Drugs; 2003; 5(5):327-34. PubMed ID: 12716219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized clinical trials of neurally mediated syncope.
    Brignole M
    J Cardiovasc Electrophysiol; 2003 Sep; 14(9 Suppl):S64-9. PubMed ID: 12950522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Midodrine in neurally mediated syncope: a double-blind, randomized, crossover study.
    Kaufmann H; Saadia D; Voustianiouk A
    Ann Neurol; 2002 Sep; 52(3):342-5. PubMed ID: 12205647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic approaches to therapy for vasovagal syncope.
    Calkins H
    Am J Cardiol; 1999 Oct; 84(8A):20Q-25Q. PubMed ID: 10568557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Syncope: pathophysiology, diagnosis, and pharmacotherapy.
    Lazarus JC; Mauro VF
    Ann Pharmacother; 1996 Sep; 30(9):994-1005. PubMed ID: 8876862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to treatment during medium-term follow-up in a series of patients with neurocardiogenic syncope.
    Lafuente EA; Martínez LC; Moguel JO; David RN; García JD; Tejeda AO; Reyes PH; González VR
    Arch Med Res; 2004; 35(5):416-20. PubMed ID: 15610912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasovagal syncope: an update on the latest pharmacological therapies.
    Schleifer JW; Shen WK
    Expert Opin Pharmacother; 2015 Mar; 16(4):501-13. PubMed ID: 25534874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for the prevention of syncope trial IV: assessment of midodrine.
    Raj SR; Faris PD; McRae M; Sheldon RS
    Clin Auton Res; 2012 Dec; 22(6):275-80. PubMed ID: 22610268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.